Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAOB | P27338 | 7/20 | 0.84 |
| ▸ | MAPT | P10636 | 2/20 | 0.84 |
| ▸ | RAB9A | P51151 | 2/20 | 0.84 |
| ▸ | GAA | P10253 | 1/20 | 0.84 |
| ▸ | MAOA | P21397 | 1/20 | 0.84 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.84 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.84 |
| ▸ | APP | P05067 | 2/20 | 0.66 |
| ▸ | F2 | P00734 | 1/20 | 0.62 |
| ▸ | PRSS1 | P07477 | 1/20 | 0.62 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.56 |
| ▸ | LMNA | P02545 | 1/20 | 0.55 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.55 |
| ▸ | PTGS1 | P23219 | 1/20 | 0.55 |
| ▸ | SLC6A2 | P23975 | 1/20 | 0.55 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.55 |
| ▸ | PTGS2 | P35354 | 1/20 | 0.55 |
| ▸ | SLC6A3 | Q01959 | 1/20 | 0.55 |
| ▸ | HIF1A | Q16665 | 1/20 | 0.55 |
| ▸ | HDAC6 | Q9UBN7 | 1/20 | 0.55 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| 4-Benzyloxyaniline SCHEMBL171449 | 0.91 | MAOB (1.00) | MAOBMAPTRAB9AGAAMAOA | |
| 4-Benzyloxyaniline SCHEMBL371743 | 0.89 | MAOB (0.96) | MAOBMAPTRAB9AGAAMAOA | |
| 4-Benzyloxyaniline SCHEMBL5376217 | 0.89 | MAOB (0.96) | MAOBMAPTRAB9AGAAMAOA | |
| SCHEMBL5121663 | 0.89 | MAOB (0.80) | MAOBMAPTRAB9AGAAMAOA | |
| SCHEMBL31542030 | 0.89 | MAOB (0.80) | MAOBMAPTRAB9AGAAMAOA | |
| SCHEMBL850999 | 0.89 | APP (0.78) | MAOBMAPTRAB9AGAAMAOA | |
| SCHEMBL5045790 | 0.86 | MAOB (0.89) | MAOBMAPTRAB9AGAAMAOA | |
| SCHEMBL6733465 | 0.86 | MAOB (0.89) | MAOBMAPTRAB9AGAAMAOA | |
| SCHEMBL29958654 | 0.85 | MAOB (0.67) | MAOBMAPTRAB9AGAAMAOA | |
| SCHEMBL10609652 | 0.84 | LMNA (0.75) | MAOBMAPTRAB9AGAAMAOA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 20 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-115124717-A | Preparation method of water-soluble polyimide sizing agent for large-tow carbon fiber precursors | 江苏海洋大学 | 2022-09-30 | — | — | CN | disclosed |
| US-11289238-B2 | Compositions for the filling of high aspect ratio vertical interconnect access (VIA) holes | HERAEUS PRECIOUS METALS NORTH AMERICA CONSHOHOCKEN LLC (US) | 2022-03-29 | — | — | US | disclosed |
| US-20210174983-A1 | COMPOSITIONS FOR THE FILLING OF HIGH ASPECT RATIO VERTICAL INTERCONNECT ACCESS (VIA) HOLES | HERAEUS PRECIOUS METALS NORTH AMERICA CONSHOHOCKEN LLC | 2021-06-10 | — | — | US | disclosed |
| WO-2021112933-A1 | COMPOSITIONS FOR THE FILLING OF HIGH ASPECT RATIO VERTICAL INTERCONNECT ACCESS (VIA) HOLES | HERAEUS PRECIOUS METALS NORTH AMERICA CONSHOHOCKEN LLC (US) | 2021-06-10 | — | — | WO | disclosed |
| WO-2020040614-A1 | PREPARATION METHOD FOR (3R,5R)-7-[2-(4-FLUROPHENYL)-5-ISOPROPYL-3-PHENYL-4-[(4-HYDROXYMETHYLPHENYLAMINO)CARBONYL]-PYRRROL-1-YL]-3,5-DIHYDROXY HEPTANOIC ACID HEMICALCIUM SALT, INTERMEDIATE USED THEREFOR, AND PREPARATION METHOD FOR INTERMEDIATE | 대원제약주식회사 | 2020-02-27 | — | — | WO | disclosed |
| WO-2018068357-A1 | NOVEL SIRT2 PROTEIN INHIBITOR AND PHARMACEUTICAL USE THEREOF | 西华大学 | 2018-04-19 | — | — | WO | disclosed |
| EP-2396316-B1 | QUINAZOLINONES AS PROLYL HYDROXYLASE INHIBITORS | JANSSEN PHARMACEUTICA NV (BE) | 2015-07-01 | — | — | EP | disclosed |
| US-9029056-B2 | Toner | CANON KABUSHIKI KAISHA (JP) | 2015-05-12 | — | — | US | disclosed |
| US-8937078-B2 | Quinazolinones as prolyl hydroxylase inhibitors | JANSSEN PHARMACEUTICA NV (BE) | 2015-01-20 | — | — | US | disclosed |
| US-8093349-B2 | Terminally modified polybranched polyimide, metal-plated terminally modified polybranched polyimide, and method for producing the same | UBE INDUSTRIES, LTD. (JP) | 2012-01-10 | — | — | US | disclosed |
| EP-2396316-A1 | QUINAZOLINONES AS PROLYL HYDROXYLASE INHIBITORS | Janssen Pharmaceutica, N.V. (BE) | 2011-12-21 | — | — | EP | disclosed |
| WO-2010093727-A1 | QUINAZOLINONES AS PROLYL HYDROXYLASE INHIBITORS | JANSSEN PHARMACEUTICA NV (BE) | 2010-08-19 | — | — | WO | disclosed |
| US-20100204226-A1 | QUINAZOLINONES AS PROLYL HYDROXYLASE INHIBITORS | JANSSEN PHARMACEUTICA NV (BE) | 2010-08-12 | — | — | US | disclosed |
| US-7649015-B2 | Cellular accumulation of phosphonate analogs of HIV protease inhibitor compounds | GILEAD SCIENCES, INC. (US) | 2010-01-19 | — | — | US | disclosed |
| US-20100009206-A1 | TERMINALLY MODIFIED POLYBRANCHED POLYIMIDE, METAL-PLATED TERMINALLY MODIFIED POLYBRANCHED POLYIMIDE, AND METHOD FOR PRODUCING THE SAME | UBE INDUSTRIES, LTD. (JP) | 2010-01-14 | — | — | US | disclosed |
| US-20060047123-A1 | Mercaptoamides as histone deacetylase inhibitors | AHMED SALEH | 2006-03-02 | — | — | US | disclosed |
| EP-0782570-A1 | SUBSTITUTED HETEROAROMATIC COMPOUNDS AND THEIR USE IN MEDICINE | THE WELLCOME FOUNDATION LIMITED (GB) | 1997-07-09 | — | — | EP | disclosed |
| WO-1996009294-A1 | SUBSTITUTED HETEROAROMATIC COMPOUNDS AND THEIR USE IN MEDICINE | THE WELLCOME FOUNDATION LIMITED (GB) | 1996-03-28 | — | — | WO | disclosed |
| EP-0031974-A2 | New urea compounds and thiourea compounds, method of preparing the new compounds, and insecticidal compositions on the basis of these compounds | DUPHAR INTERNATIONAL RESEARCH B.V (NL) | 1981-07-15 | — | — | EP | disclosed |
| US-4260411-A | HERBICIDES, FUNGICIDES | SUMITOMO CHEMICAL COMPANY, LIMITED (JP) | 1981-04-07 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100204226-A1 | QUINAZOLINONES AS PROLYL HYDROXYLASE INHIBITORS | P4HA1, EGLN3, EGLN2 | MAOB 290/4885MAPT 4308/4885RAB9A 1002/4885 |
| US-20060047123-A1 | Mercaptoamides as histone deacetylase inhibitors | HDAC1, HDAC11, HDAC2 | MAOB 870/4885MAPT 3371/4885RAB9A 3800/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.